Medexus Announces License and Supply Deal for UM171 Cell Therapy in Canada

UM171 Cell Therapy is conditionally approved in Europe as Zemcelpro® (dorocubicel)

Securing Canadian rights to a proprietary advanced clinical-stage product candidate developed in Canada adds to Medexus's medium-term product pipeline and helps build a North American allo-HSCT franchise

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 9, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that the company has secured exclusive Canadian rights to commercialize UM171 Cell Therapy, a proprietary advanced clinical stage investigational drug product that recently received conditional marketing authorization in Europe from the European Commission (or EC) as Zemcelpro® (dorocubicel), in a license and supply deal with ExCellThera, a blood stem cell expansion and metabolic fitness company, and Cordex Biologics, its wholly owned subsidiary. Zemcelpro® is a novel personalized cryopreserved hematopoietic stem cell transplantation product containing two components, namely UM171-expanded CD34+ cells (dorocubicel) and unexpanded CD34- cells, each derived from the same cord blood unit. The UM171 molecule and technology behind Zemcelpro® was discovered and developed in Canada by scientists at the Universite de Montreal. The product is used to treat hematological malignancies (blood cancers), such as leukemias and myelodysplasias. Given its current stage of development in Canada, Medexus does not expect to begin commercializing the product before calendar year 2028 or, depending on available regulatory pathways, possibly calendar year 2031.

"This product candidate is an excellent strategic fit with treosulfan, our existing hemato-oncology product, which we commercialize in Canada as Trecondyv® (treosulfan for injection)," said Ken d'Entremont, Chief Executive Officer of Medexus. "Our organization is already well acquainted with the allo-HSCT field, and, although the field continues to rapidly evolve, we see this product candidate as an important potential contribution to the Canadian market and to our medium-term product pipeline."

There were more than 843 allogeneic hematopoietic stem cell transplantation (or allo-HSCT) procedures in Canada during calendar year 2024.* Depending on the future product label approved by Health Canada, and considering the specialized nature and expected contribution of the treatment to the allo-HSCT field, Zemcelpro® (if approved by Health Canada) is expected to be an appropriate option for a significant portion of Canadian patients requiring these allo-HSCT procedures annually.

Schreibe Deinen Kommentar